Clinical Research Directory

Inclusion Criteria: * Patients who voluntarily participate in the study and have signed a written informed consent form (ICF); * Male patients aged 18 to 75 years (inclusive) at the time of signing the ICF; * Histologically or cytologically confirmed prostate cancer, without prior novel hormonal therapy (NHT) or chemotherapy; * Assessed as having metastatic hormone-sensitive prostate cancer (mHSPC), defined as: histologically or cytologically confirmed prostate cancer with distant metastases (beyond regional lymph nodes) detected by bone scan, MRI, CT, PET/CT, or pathological examination, and who have not received hormonal therapy or chemotherapy; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1; * Normal routine blood count and liver and kidney functions, expected to tolerate treatment for mHSPC; * Expected survival period ≥ 12 weeks. * Agreement to sign the ICF. Exclusion Criteria: * Patients who do not meet the inclusion criteria; * Patients currently receiving other systemic anticancer treatments (such as chemotherapy and/or immunotherapy); * Patients who have undergone organ transplantation within the past three months; * Patients with active, known, or suspected autoimmune diseases; or those testing positive for hepatitis B virus, hepatitis C virus, or HIV indicating acute or chronic infection; * Patients with severe life-threatening diseases; * Patients who have not signed the ICF; * Other conditions deemed by the researchers to make the patient unsuitable for participation in the trial.